文献速递临床试验与 GCP医学人工智能与信息学

磁共振腺苷灌注成像作为侵入性冠脉介入守门人的随机对照试验研究方案

Magnetic resonance Adenosine perfusion imaging as Gatekeeper of invasive coronary intervention (MAGnet): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2017-07-28

本研究为随机对照试验,前瞻性纳入有稳定型冠心病症状且具冠状动脉造影I类或IIa类指征的患者,1:1随机分为两组:组1接受诊断性冠状动脉造影并按现行指南行血运重建,组2接受腺苷负荷心脏磁共振(CMR)检查,若发现心肌缺血则转行冠状动脉造影。随访3年,记录主要终点(心源性死亡和非致死性心肌梗死)及非计划侵入性操作次数,并用西雅图心绞痛问卷评估症状负担和生活质量,样本量按非劣效性设计计算。

要点

  • 稳定型冠心病患者随机接受腺苷负荷CMR或直接冠状动脉造影策略。
  • CMR组仅在发现心肌缺血时转行冠状动脉造影。
  • 主要终点为心源性死亡和非致死性心肌梗死,随访3年。

核心结论

  • 若本研究能证明基于CMR的管理在稳定型冠心病患者中非劣效,该新兴模态的重要性可能进一步增加。

研究设计与样本

  • 本研究为随机对照试验,前瞻性筛查并纳入有稳定型冠心病症状且具冠状动脉造影I类或IIa类指征的患者。
  • 所有受试者接受基础心脏病学检查和指南导向药物治疗,按1:1随机分为两组。
  • 组1接受诊断性冠状动脉造影并根据现行指南行血运重建;组2接受腺苷负荷CMR,若发现心肌缺血则转行冠状动脉造影。
  • 随访计划为3年,记录主要终点(心源性死亡和非致死性心肌梗死)及非计划侵入性操作次数,并用西雅图心绞痛问卷评估症状负担和生活质量。
  • 样本量按非劣效性设计计算。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current guidelines for the diagnosis and management of patients with stable coronary artery disease (CAD) recommend functional stress testing for risk stratification prior to revascularization procedures. Cardiac magnetic resonance imaging (CMR) is a modality of choice for stress testing because of its capability to detect myocardial ischemia sensitively and specifically. Nevertheless, evidence from randomized trials evaluating a CMR-based management of stable CAD patients in comparison to a more common angiography-based approach still is limited. METHODS/DESIGN: Patients presenting themselves with symptoms indicating a stable CAD and a class I or IIa indication for diagnostic coronary angiography are prospectively screened and enrolled in the study. All subjects receive a basic cardiological work-up and guideline-directed medical therapy. A 1:1 randomization in two groups is being performed. Patients in group 1 undergo diagnostic coronary angiography and subsequent revascularization according to current guidelines. Subjects in group 2 undergo adenosine stress CMR and in case of myocardial ischemia are sent to coronary angiography. Follow-up is planned for 3 years. During this time, the number of primary endpoints (defined as cardiac death and non-fatal myocardial infarction) and unplanned invasive procedures will be documented. Furthermore, symptom burden and quality of life will be assessed by use of the Seattle Angina Questionnaire. Sample size is calculated to prove non-inferiority of the CMR-based approach. DISCUSSION: In case this study is able to accomplish its aim to prove non-inferiority of the CMR-based management in patients with stable CAD; the importance of this emerging modality may further increase. TRIAL REGISTRATION: ClinicalTrials.gov, identifier: NCT02580851 . Registered on 14 October 2015. Unique Protocol ID: 237/11.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Buckert D, Witzel S, Cieslik M, et al. Magnetic resonance Adenosine perfusion imaging as Gatekeeper of invasive coronary intervention (MAGnet): study protocol for a randomized controlled trial. Trials. 2017. PMID: 28754155. doi:10.1186/s13063-017-2101-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。